^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Rectal Cancer
    Regimen:FOLFOX
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Rectal cancer: CONTINUUM OF CARE - SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE...Patient appropriate for intensive therapy…Initial therapy...FOLFOX ± bevacizumab Rectal Cancer….Total Neoadjuvant Therapy specified as preferred- FOLFOX or CAPEOX